tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
SRPT is currently covered by 24 analysts with an average price target of $48.94. This is a potential upside of $25.11 (105.37%) from yesterday's end of day stock price of $23.83.
Sarepta Therapeutics's activity chart (see below) currently has 824 price targets and 686 ratings on display. The stock rating distribution of SRPT is 55.32% BUY, 12.77% SELL and 31.91% HOLD.
Analysts average stock forecasts to be materialized ratio is 54.84% with an average time for these price targets to be met of 249.16 days.
Highest price target for SRPT is $98, Lowest price target is $5, average price target is $30.65.
Most recent stock forecast was given by BRIAN SKORNEY from BAIRD on 04-Nov-2025. First documented stock forecast 20-Mar-2013.
Currently out of the existing stock ratings of SRPT, 52 are a BUY (55.32%), 12 are a SELL (12.77%), 30 are a HOLD (31.91%).
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
Since 04-Nov-2025
$15
$-8.83 (-37.05%)
$35
2 months 6 days ago
(04-Nov-2025)
40/61 (65.57%)
$-9.45 (-38.65%)
296
Hold
Since 16-Jun-2025
$16
$-7.83 (-32.86%)
$15
2 months 11 days ago
(30-Oct-2025)
2/11 (18.18%)
$-7.25 (-31.18%)
13
Buy
Since 22-Sep-2025
$50
$26.17 (109.82%)
$50
3 months 19 days ago
(22-Sep-2025)
0/10 (0%)
$31.35 (168.10%)
Buy
Since 22-Feb-2017
$22
$-1.83 (-7.68%)
$98
3 months 26 days ago
(15-Sep-2025)
16/25 (64%)
$4.53 (25.93%)
229
Hold
Since 09-Sep-2025
$15
$-8.83 (-37.05%)
$160
4 months 1 days ago
(09-Sep-2025)
15/20 (75%)
$-2.64 (-14.97%)
133
What is SRPT (Sarepta Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on SRPT (Sarepta Therapeutics) with a proven track record?
Which analyst has the most public recommendations on SRPT (Sarepta Therapeutics)?
Which analyst is the currently most bullish on SRPT (Sarepta Therapeutics)?
Which analyst is the currently most reserved on SRPT (Sarepta Therapeutics)?
